Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Liver Tumors
How does the use of checkpoint inhibitors for treatment of HCC impact timing of liver transplant and subsequent immunosuppression?
Related Questions
How has the GALAD score affected your practice for HCC screening?
How do you approach treatment options for patients with fibrolamellar HCC compared to "normal" HCC?
What is your evaluation approach for a new patient referral for an incidentally found liver lesion?
How does the identification of a hepatic adenoma in a male patient affect your management and evaluation?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
Do you always consider ADPCKD or ARPCKD in a patient who is incidentally found to have liver and renal cysts?
How much do you factor in a patient's frailty in selection for transplant if the underlying driver for their debility is their underlying liver disease itself?
What role is there for the use of ursodiol in relapsing hepatitis A for management of liver enzyme abnormalities and patient symptoms?
What are your biggest takeaways from the MASH-TAG 2025 conference?
How do you incorporate palliative care specialists into the care of patients with chronic liver disease, especially those who may not be transplant candidates?
